EN DE
Watch Neogen Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Neogen Corporation (NEOG) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Neogen Corporation stock $3.29, price $11.76, that is 72.0% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

NC Neogen Corporation logo Some data Nov 6, 2026

Neogen Corporation

NEOG · US
Very expensive, weak quality

Our calculation puts a fair price 72% below what the stock costs today.

Low debt
Generates free cash flow
Positive coverage
Quality 46/100
Mixed Growth (revenue 5y +13.2 %/yr in USD)
Insiders bought $10,404 (6M) · sold $114,676
Some data
Fair value $3.29 · Strongly overvalued (−72.0%)
Loss-making · -6.4% net margin (TTM)
Trails peers (1/12)
Narrow moat 15/100 · thin data
Watch Neogen Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$46.65 $4.39 Fair Value $3.29 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $4.39 – $46.65 · fair‑value band $1.02 – $6.17 · the $11.76 price screens above the $3.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Neogen in your weekly email

Every Wednesday you see whether Neogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety.

Show moreShow less

The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components.

It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services.

This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets.

Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals.

This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies.

Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Stock analysis

Neogen Corporation (NEOG) currently trades at $11.76, while our model-based Fair Value estimate is $3.29, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $3.61 per share, and 0 of the 9 models we run sit above the $11.76 price.

Bear case: the Growth DCF group reads lowest at $1.82, and 9 of the 9 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $1.02 (bear) to $6.17 (bull), the price of $11.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.

Neogen Corporation reported revenue of $870M in FY2026 versus $527M in FY2022, a compound +13.4%/yr. Reported net income was −$7.9M in FY2026.

Key figures

Market cap $2.6B Mid · P/S ratio 3.01 · EPS (TTM) $−0.2600 · Net margin −6.4% · Return on equity −2.7% · Return on assets (EBIT) 1.6% (5-year average) · Operating margin −0.8% · Revenue (TTM) $884M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 117% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −72%, NEOG screens richer than that median.

Fair Value models

Bear $1.02 Fair Value $3.29 Bull $6.17
Price $11.76 · Downside -72.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.9000 $3.50 $7.54 73
Owner Earnings $4.67 $9.95 $18.14 73
Growth DCF $0.8100 $3.01 $6.17 72
All 9 models by family
DCF Models
FCF DCF $0.9000 $3.50 $7.54 73
Owner Earnings $4.67 $9.95 $18.14 73
5Y Revenue Exit n/a $0.6100 $2.17 69
5Y EBITDA Exit $1.20 $4.41 $8.49 69
10Y Revenue Exit n/a $1.20 $3.07 64
10Y EBITDA Exit $1.02 $3.71 $7.90 62
Multiples
EV/EBITDA $1.77 $3.29 $4.81 65
Growth DCF
Growth DCF $0.8100 $3.01 $6.17 72
Rev-Margin DCF n/a $0.6300 $2.25 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 6
How calm the share price moves, does not count
Price momentum 76
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 54
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $10,404, on Oct 9, 2026. Over the same period, one person sold shares worth $114,676.

  • SaleJeremy YarwoodChief Scientific Officer9,051 shares at $12.67$114,676Nov 4, 2026
  • BuyMikheal NassifCEO, Director5× since Jan 16, 2026: 1,084 shares, avg. $11.46$12,421Oct 9, 2026

Plus 27 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.
Revenue growth 1 year
−2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.8% (2021) → −2.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+47.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−3.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +43.9% a year for the price and −6.0% for the forecasts.
Forecast 2027 (sales)+2.0%
Forecast 2028 (sales)−6.8%
Projected 2029 (sales)−5.7%
Projected 2030 (sales)−4.6%
Projected 2031 (sales)−3.5%

NEOG screens overvalued: fair value 72% below the price. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Core revenue growth and raised fiscal guidance show operational progress, while financial distress with net losses and negative cash flows highlight weak durable advantages.
Main risk: Transition risks and ongoing costs during the multi-quarter in-house production shift could delay efficiency gains and pressure margins.
Neogen is moving Petrifilm production in-house at its Lansing site, with the multi-quarter transfer set to begin in November after validating the first SKU. Core revenue grew solidly in the latest quarter and guidance for fiscal 2027 was raised, yet the expected 200-300 basis point margin lift from this shift arrives only in fiscal 2029. Will operational execution deliver those efficiencies on schedule, or will transition risks and ongoing costs extend the payoff?
Join the discussion →

Compare Neogen Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 1/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −72.0% · Bottom 25%
Profitability
Return on assets −0.2% · Below median
Net margin (12 months) −6.4% · Below median
Operating margin (12 months) −0.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 6.5% · Below median
Balance sheet
Debt / equity 0.38× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.22× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.90× · Pricier than median
Price / free cash flow (fiscal year) 80.3× · Priciest 25%
EV/EBITDA 29.1× · Priciest 25%
PEG 0.66× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)33 · sector 35
PAST (return on equity)0 · sector 17
HEALTH (low debt)81 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs NEOG
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs NEOG
DexCom, Inc DXCM $79.41 $87.35 +10% vs NEOG
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs NEOG
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs NEOG
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs NEOG
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs NEOG
Abbott Laboratories, ABT $109.93 $75.28 −32% vs NEOG
Medtronic plc MDT $101.80 $65.61 −36% vs NEOG
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs NEOG

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neogen Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Neogen Corporation Fair Value". https://www.fairvalue-calculator.com/stock/NEOG

Frequently asked questions

Is Neogen Corporation (NEOG) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $3.29 versus a price of $11.76, about 72% lower (overvalued).
What is the fair value of NEOG?
Our model-based fair value for Neogen Corporation is $3.29 (as of Nov 6, 2026), built from audited fundamentals. The current price: $11.76.
What is the quality score of NEOG?
Neogen Corporation has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neogen Corporation (NEOG)?
Our model-based price target is the fair value of $3.29 (as of Nov 6, 2026) from 9 valuation models. Cautious scenario $1.02, optimistic scenario $6.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Neogen Corporation stock forecast for 2026?
Our models put fair value at $3.29, about 72% lower versus a price of $11.76 (overvalued). Cautious scenario $1.02, optimistic scenario $6.17. The calculation is refreshed regularly with new filings.
What is the revenue of Neogen Corporation (NEOG)?
Neogen Corporation reported trailing-twelve-month revenue of about $884M (latest available figure, as of Nov 6, 2026).
What growth is priced into Neogen Corporation (NEOG)?
For today's price to be fair in a discounted-cash-flow model, Neogen Corporation would have to grow free cash flow by +47.3 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of NEOG use?
Our models discount Neogen Corporation at 11.7 %: a base by market capitalisation (mid), damped by beta 1.79, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Neogen Corporation that is +47.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has Neogen Corporation (NEOG) delivered so far?
Over the past 5 years revenue at Neogen Corporation grew +13.2 % a year. The price currently implies free-cash-flow growth of +47.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Neogen Corporation (NEOG) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Neogen Corporation (+47.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Neogen Corporation (NEOG)?
The free-cash-flow yield on the price is 1.25 %: that much free cash flow Neogen Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Neogen Corporation (NEOG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neogen Corporation it is $3.29 per share (as of Nov 6, 2026), against a price of $11.76. It is the blended result of 9 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is Neogen Corporation stock overvalued or undervalued in 2026?
As of Nov 6, 2026, NEOG trades above its calculated fair value: price $11.76, fair value $3.29, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEOG?
No. The price is what the market pays today ($11.76); the fair value is what the company's own numbers justify ($3.29). For Neogen Corporation the two are $8.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neogen Corporation worth?
The market values Neogen Corporation at about $2.6B (market capitalisation, as of Nov 6, 2026). Per share that is $11.76; our models calculate a fair value of $3.29 per share.
What do the bullish and bearish scenarios say about NEOG?
Our models span a range for Neogen Corporation: cautious scenario $1.02, base $3.29, optimistic $6.17 per share (as of Nov 6, 2026, price $11.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of NEOG?
The PEG ratio of Neogen Corporation is 0.66 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Neogen Corporation (NEOG)?
Balance-sheet figures for Neogen Corporation (as of Nov 6, 2026): return on equity −2.7%, debt of 0.38 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is NEOG from its 52-week high?
Neogen Corporation trades at $11.76, about 16% below its 52-week high of $13.98 and 117% above the low of $5.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.29 is for.
Which stocks are comparable to Neogen Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neogen Corporation stock attractive at the current price?
The data as of Nov 6, 2026: price $11.76, calculated fair value $3.29 (−72%), Quality Score 46/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEOG calculated?
We run Neogen Corporation through 9 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $3.29 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Neogen Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neogen Corporation (NEOG)?
The closing price on Nov 6, 2026 was $11.76. Our model-based fair value is $3.29, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neogen Corporation right now?
The price sits above even our optimistic bull case ($6.17). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($1.02 to $6.17). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Neogen Corporation

How large is the market capitalisation of Neogen Corporation (NEOG)?
The market capitalisation of Neogen Corporation is $2.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neogen Corporation (NEOG)?
The price-to-sales ratio of Neogen Corporation is 3.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neogen Corporation (NEOG)?
Earnings per share at Neogen Corporation are $−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neogen Corporation (NEOG)?
The net margin of Neogen Corporation is −6.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neogen Corporation (NEOG)?
The return on equity (ROE) of Neogen Corporation is −2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neogen Corporation (NEOG)?
On an EBIT basis the return on assets of Neogen Corporation is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neogen Corporation (NEOG)?
The operating margin of Neogen Corporation is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neogen Corporation (NEOG)?
Revenue at Neogen Corporation is growing +6.5% versus a year earlier (3y avg +1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neogen Corporation (NEOG)?
Earnings per share at Neogen Corporation are growing −85.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Neogen Corporation (NEOG) carry?
The net debt of Neogen Corporation is $608M (fiscal year 2026, ≈ 19.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Neogen Corporation in the live analysis

One click puts Neogen Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.